Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (11-20 of 270) with videos related to

Pageof 27
Sort By:
Clinical Medicine Reviews in Therapeutics|October 19, 2010
Zidovudine and Lamivudine for HIV InfectionPeter L Anderson, Joseph E Rower
Current Infectious Disease Reports|July 27, 2001
Clinical Pharmacologic Considerations for HIV-1 Protease InhibitorsPeter L. Anderson, Courtney V. Fletcher
The Journal of Antimicrobial Chemotherapy|May 24, 2006
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovirPeter L Anderson, Thomas N Kakuda
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 15, 2010
Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessmentMichael F Wempe, Peter L Anderson
British Journal of Clinical Pharmacology|August 16, 2022
Long-acting injectable Cabotegravir: How drug concentrations could help guide patient managementJose R Castillo-Mancilla, Peter L Anderson
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 12, 2004
Stability of zidovudine with oxytocin in a simulated Y-site injectionPeter L Anderson, Susan Miller, Lane R Bushman
Acta Diabetologica|May 12, 2015
Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory settingPetter Bjornstad, Peter L Anderson, David M Maahs
Journal of Acquired Immune Deficiency Syndromes (1999)|July 19, 2016
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender WomenPeter L Anderson, Daniel Reirden, Jose Castillo-Mancilla
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2013
Clinical pharmacokinetics of antiretroviral drugs in older personsJohn C Schoen, Kristine M Erlandson, Peter L Anderson
AIDS (London, England)|December 29, 2004
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be relatedThomas N Kakuda, Peter L Anderson, Stephen L Becker
Pageof 27

Showing results (11-20 of 270) with videos related to

Sort By:
Pageof 27
Clinical Medicine Reviews in Therapeutics|October 19, 2010
Zidovudine and Lamivudine for HIV InfectionPeter L Anderson, Joseph E Rower
Current Infectious Disease Reports|July 27, 2001
Clinical Pharmacologic Considerations for HIV-1 Protease InhibitorsPeter L. Anderson, Courtney V. Fletcher
The Journal of Antimicrobial Chemotherapy|May 24, 2006
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovirPeter L Anderson, Thomas N Kakuda
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 15, 2010
Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessmentMichael F Wempe, Peter L Anderson
British Journal of Clinical Pharmacology|August 16, 2022
Long-acting injectable Cabotegravir: How drug concentrations could help guide patient managementJose R Castillo-Mancilla, Peter L Anderson
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 12, 2004
Stability of zidovudine with oxytocin in a simulated Y-site injectionPeter L Anderson, Susan Miller, Lane R Bushman
Acta Diabetologica|May 12, 2015
Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory settingPetter Bjornstad, Peter L Anderson, David M Maahs
Journal of Acquired Immune Deficiency Syndromes (1999)|July 19, 2016
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender WomenPeter L Anderson, Daniel Reirden, Jose Castillo-Mancilla
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2013
Clinical pharmacokinetics of antiretroviral drugs in older personsJohn C Schoen, Kristine M Erlandson, Peter L Anderson
AIDS (London, England)|December 29, 2004
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be relatedThomas N Kakuda, Peter L Anderson, Stephen L Becker
Pageof 27